Chapter 1. Lipoprotein Physiology
Chapter 2. Epidemiology of Blood Lipids and Lipoproteins
Chapter 3. Lipoprotein(a)
Chapter 4. Lipoproteins and Cardiovascular Disease Risk
Chapter 5. Detection and Treatment of Children and Adolescents with Dyslipidemia
Chapter 6. Type 2 Diabetes Mellitus and Dyslipidemia
Chapter 7. Type 1 Diabetes Mellitus and Dyslipidemia
Chapter 8. Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome
Chapter 9. Dyslipidemia in HIV-infected Patients
Chapter 10. Monogenic Hypercholesterolemia
Chapter 11. Primary Hypertriglyceridemia
Chapter 12. Genetic Disorders of HDL Metabolism
Chapter 13. Sitosterolemia and Other Rare Sterol Disorders
Chapter 14. Genetic Abetalipoproteinemia & Hypobetalipoproteinemia
Chapter 15. Drug-induced Dyslipidemia
Chapter 16. Lipodystrophies and Dyslipidemias
Chapter 17. Novel Genes for Dyslipidemias: Genome-Wide Association Studies
Chapter 18. Perspectives on Cholesterol Guidelines
Chapter 19. Nutrition and Coronary Heart Disease Prevention
Chapter 20. Phytosterol Therapy
Chapter 21. N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease
Chapter 22. Polyphenols for Cholesterol Management
Chapter 23 - Dietary Supplements for Cholesterol Management
Chapter 24. Statins: Risk-Benefits and Role in Treating Dyslipidemias
Chapter 25. Fibrates: Risk-Benefits and Role in Treating Dyslipidemias
Chapter 26. Niacin: Risk-Benefits and Role in Treating Dyslipidemias
Chapter 27. Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias
Chapter 28. Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias
Chapter 29. Low Density Lipoprotein (LDL) Apheresis
Chapter 30. Novel Lipid Lowering Agents
About the Author: Abhimanyu Garg, MBBS, MD
Professor of Internal Medicine
UT Southwestern Medical Center
Department of Internal Medicine
5323 Harry Hines Blvd
Dallas, TX 75390
TEL 214-648-2895
